# Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance

Source: https://onco.cc/trials/nct07285057/  
OnCo record `nct07285057` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Flotufolastat F-18 in Prostate cancer, run by Icahn School of Medicine at Mount Sinai, now recruiting.

## Summary

Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance is a phase 2 interventional study registered as NCT07285057 by Icahn School of Medicine at Mount Sinai, with 120 participants planned, started 2026-02-10 and due to reach its primary completion in 2027-05-01. Interventions recorded: rhPSMA-7.3 (18F) PET/CT Imaging (Flotufolastat F18, POSLUMA®), Flotufolastat F18. Conditions recorded: Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma.

Linked to the drug Flotufolastat F-18 because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07285057
- Phase: 2
- Setting: Diagnostic Utility of rhPSMA-7.3 (18F) PET /CT Imaging in Patients With Prostate Cancer on Active Surveillance
- Sponsor: Icahn School of Medicine at Mount Sinai
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT07285057: https://clinicaltrials.gov/study/NCT07285057

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Flotufolastat F-18](https://onco.cc/drugs/flotufolastat/)

---
JSON: https://onco.cc/api/v1/entities/nct07285057.json